GlassScriptPhysician profile
Michael J Spedick
NPI 1720054836
$1,360.32
in general payments reported to CMS, 2019-2025
14 companies · $478 in 2025
The $478 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $320 · 2022: $41.94 · 2023: $281 · 2024: $240 · 2025: $478.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $999.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $998.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $252.90 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $186.10 | 2023-2025 | Tryptyr, Rhopressa, Rocklatan |
| Allergan, INC. | $182.13 | 2019 | |
| Bausch & Lomb Americas INC. | $164.55 | 2022-2025 | Vyzulta, Xiidra, Scoutpro Osmolarity System |
| Dompe US, INC. | $160.57 | 2019-2025 | Oxervate |
| Santen INC. | $110.26 | 2023 | Verkazia |
| Sun Pharmaceutical Industries INC. | $97.86 | 2019-2025 | Cequa |
| Abbvie INC. | $78.59 | 2023-2024 | Ozurdex, Vuity, Lumigan |
| Regeneron Healthcare Solutions, INC. | $36.57 | 2023-2024 | Eylea |
| Biotissue Holdings INC. | $26.98 | 2022-2023 | |
| Johnson & Johnson Surgical Vision, INC. | $17.66 | 2025 | Tecnis Iol |
| Novartis Pharmaceuticals Corporation | $17.04 | 2023 | |
| Oyster Point Pharma, INC. | $14.68 | 2022 | |
| Harrow Eye, LLC | $14.43 | 2023 | Vevye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Spedick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.